Related Experiment Video
Updated: Aug 16, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer
P E Werthman1, K E Drazan, J T Rosenthal
1Department of Surgery, University of California at Los Angeles 90095, USA.
Purpose:
This study was designed to examine the potential for adenoviral-mediated gene therapy in primary and metastatic bladder cancer.
Materials And Methods:
Orthotopic and intraperitoneal bladder tumors were established after delivery of 1 x 10(6) MBT-2 cells into syngeneic mice. Gene transfer was accomplished via intravesical or intraperitoneal instillation by using an E-1 deleted adenovirus encoding LacZ or human p53. Successful tumor transduction was confirmed in tumor DNA and mRNA by polymerase chain reaction. Detection of recombinant gene product was detected by histochemical staining (X-gal) and Western blot.
Results:
Palpable tumors developed 18 days following implantation. LacZ and p53 mRNA were present in tumor and adjacent normal tissue after bladder and intraperitoneal vector administration. Recombinant gene products were identified by histochemistry and Western blot.
Conclusion:
Bladder tumor-directed gene transfer using adenoviral vectors is an efficient and powerful tool for evaluating the adjuvant role of therapeutic gene products.
Insights
Adenoviral-mediated gene therapy shows potential for bladder cancer treatment. This study confirmed efficient gene transfer into bladder tumors, paving the way for evaluating new therapeutic gene products.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Bladder cancer presents a significant therapeutic challenge, necessitating novel treatment strategies.
- Gene therapy offers a promising avenue for targeting cancer cells directly.
- Adenoviral vectors are effective tools for gene delivery in preclinical models.
Purpose of the Study:
- To investigate the efficacy of adenoviral-mediated gene therapy in primary and metastatic bladder cancer models.
- To assess the feasibility of gene transfer into bladder tumors using adenoviral vectors.
Main Methods:
- Syngeneic mouse models with orthotopic and intraperitoneal bladder tumors were established.
- Adenoviral vectors encoding LacZ or human p53 were administered via intravesical or intraperitoneal instillation.
- Tumor transduction was confirmed using polymerase chain reaction (PCR) for DNA and mRNA, and protein expression was detected via histochemistry and Western blot.
Main Results:
- Palpable tumors formed within 18 days post-implantation.
- Successful LacZ and p53 mRNA transduction was observed in both tumor and adjacent normal tissues.
- Recombinant gene products were successfully detected, confirming successful gene transfer and expression.
Conclusions:
- Adenoviral vectors enable efficient gene transfer into bladder tumors.
- This approach serves as a powerful tool for investigating the therapeutic potential of gene products in bladder cancer.
